Tag Archives: Kyle Rose

Canaccord Genuity Believes Alphatec Holdings (NASDAQ: ATEC) Won’t Stop Here

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) yesterday and set a price target of $16.00. The company’s shares closed last Tuesday at $13.73, close to its 52-week high of $14.97. According

Canaccord Genuity Maintains a Buy Rating on SeaSpine Holdings (SPNE)

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on SeaSpine Holdings (SPNE – Research Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $16.11. According to TipRanks.com, Rose is a 5-star analyst

Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Galmed Pharmaceuticals (GLMD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATEC – Research Report), Galmed Pharmaceuticals (GLMD – Research Report) and Daré Bioscience (DARE – Research Report) with bullish sentiments.

Canaccord Genuity Maintains Their Buy Rating on Sientra (SIEN)

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Sientra (SIEN – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Monday at $4.75. According to TipRanks.com, Rose is a 5-star analyst with

Intersect ENT (XENT) Gets a Hold Rating from Canaccord Genuity

In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Hold rating on Intersect ENT (XENT – Research Report), with a price target of $18.00. The company’s shares closed last Thursday at $17.70. According to TipRanks.com, Rose is

Canaccord Genuity Believes SeaSpine Holdings (NASDAQ: SPNE) Won’t Stop Here

In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Buy rating on SeaSpine Holdings (SPNE – Research Report), with a price target of $21.00. The company’s shares closed last Tuesday at $15.12, close to its 52-week high